A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second‐ and third‐generation tyrosine kinase inhibitors

A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second‐ and third‐generation tyrosine kinase inhibitors

Abstract Background Treatment with tyrosine kinase inhibitors (TKIs) for patients with chronic myeloid leukemia (CML) is effective but needs to continue for several years, possibly indefinitely. Although generally safe, TKI may have hitherto poorly recognized effects in the quality of life (QoL) of...

Full description

Bibliographic Details
Main Authors: Alejandro Zulbaran‐Rojas, Huei‐Kan Lin, Qiuling Shi, Loretta A. Williams, Binsah George, Guillermo Garcia‐Manero, Elias Jabbour, Susan O’Brien, Farhad Ravandi, William Wierda, Zeev Estrov, Gautam Borthakur, Tapan Kadia, Charles Cleeland, Jorge E. Cortes, Hagop Kantarjian
Format: Article
Language:English
Published: Wiley 2018-11-01
Series:Cancer Medicine
Subjects:
BCR‐ABL
chronic myeloid leukemia
symptom burden
tyrosine kinase inhibitors
Online Access:https://doi.org/10.1002/cam4.1808

Internet

https://doi.org/10.1002/cam4.1808

Similar Items